Summary & Overview

Kidney and Ureter Procedures for Neoplasm without CC/MCC: Inpatient Reimbursement Overview

DRG 658 encompasses kidney and ureter procedures performed for neoplasm without Complication or Comorbidity or Major Complication or Comorbidity, defining a lower-complexity surgical admission. It matters for inpatient reimbursement because Diagnosis-Related Group assignment determines standardized Medicare payment based on clinical case mix and documented resource intensity.

Kidney and Ureter Procedures for Neoplasm without CC/MCCDRG Kidney and Ureter Procedures for Neoplasm without CC/MCCDRG 658Diagnosis-Related GroupInpatient ReimbursementMedicareUrologyNephrectomyUreterectomy

DRG 658 Overview

DRG 658 covers inpatient admissions for kidney and ureter surgical procedures performed for neoplasm when no Complication or Comorbidity and no Major Complication or Comorbidity are present. This Diagnosis-Related Group groups cases by clinical complexity and resource use to determine standardized Medicare payment for the hospitalization. It is important for hospitals because the classification affects base payment and impacts coding, billing, and expected reimbursement for urologic oncology surgeries. Accurate principal diagnosis and procedure coding determine assignment to this Diagnosis-Related Group and corresponding payment.

Clinical Trials

Perioperative randomized trials comparing minimally invasive nephrectomy techniques versus open surgery for localized renal neoplasm: These studies evaluate surgical approach (laparoscopic/robotic partial or radical nephrectomy versus open procedures) in adults with localized kidney tumors without significant comorbid complications, measuring intraoperative metrics, hospital length of stay, perioperative complications, and short-term oncologic outcomes. This research is relevant because surgical approach directly affects inpatient resource use, complication rates that drive CC/MCC classification, and reimbursement implications for DRG 658.
Comparative effectiveness studies of renal-sparing surgery versus radical nephrectomy in small renal masses focusing on functional and economic outcomes: Observational cohorts or pragmatic trials enrol patients with T1 renal neoplasms eligible for either partial nephrectomy or radical nephrectomy to compare postoperative renal function preservation, readmission rates, downstream dialysis risk, and total episode-of-care costs. Payers and providers need this evidence to balance immediate inpatient costs and longer-term morbidity that influence post-acute utilization and overall value of care under this DRG.
Post-discharge outcomes and survivorship studies assessing readmissions, complications, and health-related quality of life after kidney/ureter cancer surgery: Prospective registry-based or longitudinal cohort studies follow patients discharged after nephrectomy or ureteral tumor surgery to identify predictors of 30- and 90-day readmission, late surgical complications, surveillance adherence, and survivorship needs. These studies inform care pathways, discharge planning, and resource allocation because readmissions and complications alter inpatient case-mix, affect reimbursement patterns, and are key targets for cost and quality improvement for DRG 658.

Related Codes

654-MAJOR-BLADDER-PROCEDURES-WITH-CC

Major Bladder Procedures with CC: Inpatient Reimbursement Overview

655-MAJOR-BLADDER-PROCEDURES-WITHOUT-CC-MCC

Major Bladder Procedures without CC/MCC: Inpatient Reimbursement Overview

664-MINOR-BLADDER-PROCEDURES-WITHOUT-CC-MCC

Minor Bladder Procedures without CC/MCC: Inpatient Reimbursement Overview

687-KIDNEY-AND-URINARY-TRACT-NEOPLASMS-WITH-CC

Kidney and Urinary Tract Neoplasms with CC: Inpatient Reimbursement Overview

670-TRANSURETHRAL-PROCEDURES-WITHOUT-CC-MCC

Transurethral Procedures without CC/MCC: Inpatient Reimbursement Overview

662-MINOR-BLADDER-PROCEDURES-WITH-MCC

Minor Bladder Procedures with MCC: Inpatient Reimbursement Overview

656-KIDNEY-AND-URETER-PROCEDURES-FOR-NEOPLASM-WITH-MCC

Kidney and Ureter Procedures for Neoplasm with MCC: Inpatient Reimbursement Overview

671-URETHRAL-PROCEDURES-WITH-CC-MCC

Urethral Procedures with CC/MCC: Inpatient Reimbursement Overview

660-KIDNEY-AND-URETER-PROCEDURES-FOR-NON-NEOPLASM-WITH-CC

Kidney and Ureter Procedures for Non-Neoplasm with CC: Inpatient Reimbursement Overview

700-OTHER-KIDNEY-AND-URINARY-TRACT-DIAGNOSES-WITHOUT-CC-MCC

Other Kidney and Urinary Tract Diagnoses without CC/MCC: Inpatient Reimbursement Overview

Showing 1–10 of 41

Trek Health ingests and normalizes Transparency in Coverage data and payer policy updates to give provider organizations a clear view of how commercial reimbursement behaves across markets, payers, and services. Our platform transforms raw payer disclosures into structured intelligence that supports contract evaluation, payer negotiations, and service line strategy. By combining market benchmarks with ongoing policy visibility, Trek helps teams identify variability, risk, and opportunity in commercial reimbursement. The result is faster insight, stronger negotiating positions, and more informed financial decisions.